Identification of HCC Subtypes With Different Prognosis and Metabolic Patterns Based on Mitophagy

Yao Wang†, Zhen Wang†, Jingjing Sun† and Yeben Qian†*

†Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China, ‡Department of General Surgery, Feixi County People’s Hospital, Hefei, China

Background: Mitophagy is correlated with tumor initiation and development of malignancy. However, HCC heterogeneity with reference to mitophagy has yet not been systematically explored.

Materials and Methods: Mitophagy-related, glycolysis-related, and cholesterol biosynthesis-related gene sets were obtained from the Reactome database. Mitophagy-related and metabolism-related subtypes were identified using the ConsensusClusterPlus algorithm. Univariate Cox regression was analysis was performed to identify prognosis-related mitophagy regulators. Principal component analysis (PCA) was used to create composite measures of the prognosis-related mitophagy regulators (mitophagyscore). Individuals with a mitophagyscore higher or lower than the median value were classified in high- or low-risk groups. Kaplan-Meier survival and ROC curve analyses were utilized to evaluate the prognostic value of the mitophagyscore. The nomogram and calibration curves were plotted using the “rms” R package. The package “limma” was used for differential gene expression analysis. Differentially expressed genes (DEGs) between high- and low-risk groups were used as queries in the CMap database. R package “pRRophetic” and Genomics of Drug Sensitivity in Cancer (GDSC) database were used to determine the sensitivity of 21 previously reported anti-HCC drugs.

Results: Three distinct HCC subtypes with different mitophagic accumulation (low, high, and intermediate mitophagy subtypes) were identified. High mitophagy subtype had the worst outcome and highest glycolysis level. The lowest degree of hypoxia and highest cholesterol biosynthesis was observed in the low mitophagy subtype; oncogenic dedifferentiation level in the intermediate mitophagy subtype was the lowest. Mitophagyscore could serve as a novel prognostic indicator for HCC. High-risk patients had a poorer prognosis (log-rank test, \(p < 0.001\)). The area under the ROC curve for mitophagyscore in 1-year survival was 0.77 in the TCGA cohort and 0.75 in the ICGC cohort. Nine candidate small molecules which were potential drugs for HCC treatment were identified from the CMap database. A decline in the sensitivity towards 21 anti-HCC drugs was observed in low-risk patients by GDSC database. We also identified a novel key gene, SPP1, which was highly associated with different mitophagic subtypes.
Conclusion: Based on bioinformatic analyses, we systematically examined the HCC heterogeneity with reference to mitophagy and observed three distinct HCC subtypes having different prognoses and metabolic patterns.

Keywords: HCC, mitophagy, metabolism, ICGC data portal, the cancer genome atlas program

INTRODUCTION

Hepatocellular carcinoma (HCC), a highly heterogeneous solid malignancy, is the third leading cause of cancer-related deaths worldwide. The overall 5-years survival rate for HCC is 18%, and it is the second deadliest malignancy after pancreatic carcinoma (Beal et al., 2017). Tumor heterogeneities, including microenvironmental discrepancies and morphological heterogeneity, are frequently reported in HCC and play a major role in tumor progression and resistance to treatment. (Li and Wang, 2016), (Borgia et al., 2021), (Atwa et al., 2021)

A special form of autophagy, mitophagy, is a mechanism for mitochondrial quality control. Damaged, defective, or dysfunctional mitochondria are identified by the mitophagic machinery and subsequently degraded in the lysosome (Vara-Perez et al., 2019). The PINK1/Parkin pathway is among the most investigated pathway in mitophagy. Ordinarily, the serine/threonine PTEN-induced putative kinase 1 (PINK1) is transported to the inner mitochondrial membranes by the translocase of the outer membrane (TOM) and the translocase of the inner membrane (TIM) complexes. The presenilin-associated rhomboid-like (PARL) proteins cleave PINK1 protein and target it for degradation to the mitochondrial proteasome. Therefore, the intracellular level of PINK1 is relatively low. Mitochondrial depolarization stops the translocation of PINK1. PARL upon phosphorylation by PDK2 loses its ability to cleave PINK1. (Jin et al., 2010), (Lopez Domenech et al., 2018), (Wang et al., 2011) PINK1 accumulation promotes the E3 ubiquitin ligase activity of Parkin by the phosphorylation of serine 65 residue of the ubiquitin-like domain of Parkin. The impaired mitochondria are isolated when critical mitochondrial proteins such as MFN1, MFN2, and Miro1, are ubiquitinated by Parkin. (Glauser et al., 2011), (Chen and Dorn, 2013) In addition, phosphorylation of ubiquitin chains by PINK1 further enhances Parkin recruitment and activation (Durcan and Fon, 2015). Subsequently, p62 and OPTN (autophagy cargo adaptors) recognize the polyubiquitylation of mitochondrial proteins and ultimately the autophagic machinery degrades the complex formed by the interaction of mitochondrial proteins and LC3. (Wong and Holzbaur, 2014), (Geisler et al., 2010)

Hepatocytes each contain approximately 1,000 mitochondria, which constitute about 18% of cell by volume (Koh et al., 2018). Previous studies have reported that Mitochondria are a major source of reactive oxygen species (ROS) production. Meanwhile, immoderate ROS lead to DNA, protein, and lipids lesion that tightly associated to the pathogenesis of cancers. By the way, Over 90% of HCCs are intimately linked to hepatic injury and inflammation. Dysfunctional mitochondria allows the release of ROS and mitochondrial DNA (mtDNA) into the cytosol.
gene expression, and the epigenetically regulated (EREG)-mRNAsi reflecting epigenetically regulated mRNAsi. The stemness index contributes to elucidation of the dedifferentiation of tumor cells, and higher index values were closely associated with the progression of multiple types of cancers (Malta et al., 2018). The mRNAsi scores for the TCGA-LIHC samples were obtained from previous studies (Malta et al., 2018). mRNAsi score is a novel gene expression-based stemness index for assessing the degree of oncogenic dedifferentiation; the value ranges from (0,1).

**Identification of Mitophagy Subtypes**

Unsupervised hierarchical clustering was performed using the “ConsensusClusterPlus” package in R to cluster the mitophagy regulators. The parameter settings were as follows: reps = 50, pItem = 0.8, pFeature = 1, and distance = Euclidean (Wilkerson and Hayes, 2010). Mitophagy subtypes were obtained. For a total of 97 genes from the cholesterol biosynthesis and glycolysis gene sets, unsupervised hierarchical clustering was performed with the above settings and different metabolic classifications were obtained.

We also calculated the enrichment scores for each sample in the cholesterol biosynthesis and glycolysis gene sets by the single sample Gene Set Enrichment Analysis (ssGSEA) algorithm (Supplementary Table S2) (Hänzelmann et al., 2013).

**Construction and Validation of the Prognostic Mitophagy Regulator-Based Signature**

Univariate Cox analysis was used to distinguish between prognosis-related mitophagy regulators. The overlapping prognostic mitophagy regulators (p < 0.05) in TCGA-LIHC and ICGC-LIRI-JP cohorts were selected for further analyses. Principal component analysis (PCA) was performed to establish the mitophagy-related gene signature. The sum of the principal components 1 and 2 gave the mitophagy regulator signature scores (mitophagyscore). The approach focused on the signature scores in the set with the largest block of well correlated (or anticorrelated) genes, while down-weighing the contributions from genes that were not associated with other set members. The mitophagyscore was identified by performing a method similar to GCI. (Sotiriou et al., 2006), (Zeng et al., 2019)

We calculated the mitophagyscore for each patient and divided them into the high-risk and low-risk groups based on the median in their respective cohorts. K-M analysis and log-rank test were used to evaluate the prognostic value of the mitophagyscore. Based on tumor stage and mitophagyscore we tested were used to evaluate the prognostic value of the intersecting DEGs was performed using the "clusterProfiler" package in R (Liu et al., 2020). Enrichment analysis results of the top 20 enriched KEGG and GO terms with smallest adjusted p-value are displayed in dotplot. Then we rerun the enrichment analysis by Metascape database (http://metascape.org) to verify each top 20 enriched KEGG and GO terms. The intersection of DEGs was used as the input for the Connectivity map (CMap) database (https://portals.broadinstitute.org/cmap/). The selection criteria were as follows: p-value<0.05, enrichment < -0.8 (Shen et al., 2019).

**Drug Sensitivity Prediction**

Drug-response prediction was assessed using the "pRRophetic" package in R, where the half-maximum inhibitory concentration (IC50) of each patient was estimated using Ridge’s regression, and the accuracy of the prediction was estimated by 10-fold cross-validation, based on the Genomics of Drug Sensitivity in Cancer (GDSC) database (Ding et al., 2021).

**Identification of DEGs Among Different Mitophagy Subtypes**

We obtained multiple distinct mitophagy subtypes and gene differential expression analysis was performed using the "limma" package in R for pairwise analyses to evaluate specific DEGs between the subtypes. The screening criteria were set as follows: | log2FC |> 1 and adjusted p < 0.05. This process was performed for both TCGA-LIHC and ICGC-LIRI-JP cohorts simultaneously. The intersecting DEGs from the two cohorts were considered as candidate DEGs which were highly correlated with the mitophagy subtypes. The difference in expression of candidate DEGs between tumor and normal tissues was estimated using the GEPIA database. The expression of candidate DEGs in different tumor stages and their effect on HCC prognosis were assessed using the GEPIA database (Tang et al., 2017). The HPA database was used to obtain protein expression levels of candidate DEGs based on immunohistochemistry (IHC) staining and IHC image data downloaded from the HPA database (Song et al., 2020).

**Statistical Analysis**

Statistical tests were carried out by R software for statistical computing (R version 4.0.4). Significance was estimated via the nonparametric Wilcoxon test in comparisons between two groups, while via Kruskal-Wallis test in multiple comparisons. Categorical data were tested by the chi-square test and the chi-square test for trends. K-M analysis for OS and Progression-free survival (PFS) was performed between different subgroups, followed by log-rank test. Operating characteristic curve (ROC) for 1-year survival was established for evaluation of the predictive efficacy of the mitophagyscore. Correlation analyses were performed using Spearman’s correlation. A statistical p
FIGURE 1 | In TCGA cohort, the boxplot of the expression level of the mitophagy regulators in normal and HCC samples (B). In ICGC cohort, the boxplot of the expression level of the mitophagy regulators in normal and HCC samples (C). The location of CNV alteration of mitophagy regulators on chromosomes using TCGA cohort (D). The CNV variation frequency of mitophagy regulators in TCGA cohort. The height of the column represented the alteration frequency. The deletion frequency, green dot; The amplification frequency, red dot (E). The mutation frequency of mitophagy regulators in 364 patients with HCC from TCGA-LIHC cohort. Each column represented individual patients. The upper barplot showed TMB, The number on the right indicated the mutation frequency in each regulator. The right barplot showed the proportion of each variant type. The stacked barplot below showed fraction of conversions in each sample. The asterisks represented the statistical $p$ value (*$p < 0.05$; **$p < 0.01$; ***$p < 0.001$; ****$p < 0.0001$).
FIGURE 2 | Identify different mitophagy subtypes (A) Consensus matrices of the TCGA cohort for k = 3. (B) Unsupervised clustering of overlapping mitophagy regulators in TCGA cohorts to classify patients into different subtypes (cluster A-C). Grade, stage, gender, survival status and age were utilized as patient annotations (C) Survival analyses for the three clusters in TCGA cohort including 102 cases in cluster A, 131 cases in cluster B, and 109 cases in cluster C. Kaplan-Meier curves with Log-rank p value < 0.001 showed a significant survival difference among three clusters. The cluster B showed significantly worse OS than the other two clusters. (D) Consensus matrices of the ICGC cohort for k = 3 (E) Unsupervised clustering of overlapping mitophagy regulators in ICGC cohorts to classify patients into different subtypes (cluster A-C). Stage, gender, survival status and age were utilized as patient annotations (F) Survival analyses for the three clusters in ICGC cohort including 58 cases in cluster A, 56 cases in cluster B, and 115 cases in cluster C. Kaplan-Meier curves with Log-rank p value < 0.001 showed a significant survival difference among three clusters. The cluster B showed significantly worse OS than the other two clusters.
FIGURE 3 | The gene expression of each mitophagy regulators between the different mitophagy subtypes in TCGA LIHC (A) and ICGC LIRI-JP (B). The enrichment score of three mitophagy-relayed gene sets between the different mitophagy subtypes in TCGA LIHC (C) and ICGC LIRI-JP (D). The upper and lower ends of the boxes represented interquartile range of values. The lines in the boxes represented median value, and black dots showed outliers. The asterisks represented the statistical p value (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
value of 0.05 was considered indicative of significance. Enrichment analysis of all Reactome pathways performed by GSEA (https://software.broadinstitute.org/gsea/index.jsp). Under the premise of NOM p-val less than 0.05, only the top ten pathways with highest absolute values of the normalized Enrichment Score (NES) are presented as the most enriched items.

RESULTS

Landscape of Mitophagy Regulators in Liver HCC

We separately investigated the levels of expression of mitophagy regulators in TCGA-LIHC and ICGC-LIRI-JP cohorts (Figure 1A, B). Genes detected in less than two cohorts were excluded and we obtained a total of 26 mitophagy regulators in this study. However, the expression of TOMM6 was zero in more than 90% of samples in TCGA cohort. Therefore, TOMM6 were not included for further analysis of TCGA cohort (Zoni et al., 2019). Among the 26 genes, only PINK1, MAPILC3A and UBB were significantly downregulated in tumor samples as compared to normal samples and other genes were significantly upregulated in tumor samples. The locations of CNV alterations in mitophagy regulators on chromosomes are shown in Figure 1C. Compared with normal liver tissues, PINK1 and MFN2 showed a distinctly higher proportion of copy number alterations and 13 mitophagy regulators showed a higher proportion of gain in CNVs (e.g. TOMM20 and MLN1) (Figure 1D). Mitophagy regulators were rarely mutated; the frequency was 5.77%. The results indicated that VDAC1 and UBC exhibited the highest mutation frequency.

Description of Mitophagy Subtypes in Liver HCC

Consistent clustering of 26 mitophagy regulators was established using the “ConsensusClusterPlus” package in R and all tumor samples were classified into three subtypes (cluster A, cluster B, and cluster C) (Figure 2A). The gene expression pattern of mitophagy regulators is shown using a heatmap of hierarchical clustering (Figure 2B). Kaplan-Meier survival analyses were performed for the three clusters (Figure 2C). The analysis procedure was identical for both TCGA-LIHC and ICGC-LIRI-JP cohorts (Figure 2D-F). A vast majority of the mitophagy regulators had their highest expression levels in cluster B and the lowest in cluster A (Figure 3A, B). ssGSEA was employed to impute the enrichment scores of mitophagy-related pathways. Neither in the TCGA-LIHC nor the ICGC-LIRI-JP cohorts, the enrichment scores of mitophagy pathway and receptor mediated mitophagy pathway were significantly highest in cluster B (Figure 3C, D).

We then defined the samples as low mitophagy (cluster A), high mitophagy (cluster B), and intermediate mitophagy (cluster C) subtypes. Patients with high mitophagy subtype had the worst prognoses.

A total of 97 genes from cholesterol biosynthesis and glycolysis gene sets were used for unsupervised hierarchical clustering and three metabolic classifications were obtained in the TCGA-LIHC cohort (mixed, quiescent, and glycolytic; Figure 4A). The gene expression patterns for cholesterol biosynthesis and glycolysis genes in the TCGA-LIHC cohort are shown in Figure 4B. Cluster A, the low mitophagy subtype, showed a particularly prominent advantage in quiescent metabolic classification (71.4%) and was inferior in glycolytic classification (2.9%). In contrast, there was a significantly greater proportion of mixed metabolic classification and a smaller proportion of quiescent classification in clusters B and C as compared to cluster A (Chi-square test p-value = 0.0001; Figure 4C); a smaller proportion of mixed metabolic classification and a larger proportion of quiescent classification was found in cluster B as compared to cluster C (Chi-square test p value = 0.023; Figure 4D)

Kruskal-Wallis test showed significant differences in the enrichment scores for cholesterol biosynthesis and glycolysis genes between the mitophagy subtypes. Cluster A had the lowest median enrichment score for glycolysis genes and highest enrichment score for cholesterol biosynthesis genes, while cluster B had the highest median enrichment score for glycolysis genes (Figure 4D, E). This indicated that the mitophagy subtypes were strongly associated with the metabolic differences in liver HCC.

We compared the gene expression of HIF1A, a hypoxia marker, between different mitophagy subtypes, and observed a significant downregulation in cluster A (Figure 4F).

To examine the change in biological functions upon the increase in mitophagic accumulation, we performed GSEA for clusters A and B. Ten most enriched terms in cluster B are shown in Figure 4H; four other terms were enriched in cluster A (Figure 4I) including the terminal pathway of the complement system, biosynthesis of maresin-like SPMs, fructose catabolism, and tyrosine catabolism pathways.

Prognostic Role of Mitophagy Regulators in HCC

Univariate analysis of mitophagy regulators for OS indicated that there were 18 potential prognostic mitophagy regulators in the TCGA-LIHC cohort and 15 in the ICGC-LIRI-JP cohort (Supplementary Figure S1A, B). Ultimately, 12 mitophagy regulators were identified as predictors for poor prognosis in both cohorts, including PGAM5, TOMM22, TOMM5, MFN1, CSNK2A2, VDAC1, TOMM40, FUNDC1, CSNK2A1, CSNK2B, RPS27A, and SRC were included in subsequent analyses. PCA analysis reduced the above 12 mitophagy regulators into two principal components, PC1 and PC2. We summed the values of PC1 and PC2 for each patient and calculated the mitophagyscore.

Patients were divided into two groups according to the median values for mitophagyscore (median value in TCGA = 0.060; median value in ICGC = -10.353). Patients with mitophagyscores below the median were classified in the low-risk group (TCGA:n = 171; ICGC:n = 114) and those with higher
Identify different metabolic subtypes (A) Consensus matrices of the TCGA cohort for k = 3 (B) Unsupervised clustering of total 97 genes from the cholesterol biosynthesis and glycolysis gene sets in TCGA cohorts to classify patients into different subtypes (mixed, quiescent, and glycolytic). Grade, stage, gender, survival status and age were utilized as patient annotations (C) The proportion of metabolic subtypes in the three mitophagy subtypes. Mixed subtype, red; quiescent subtype, green; glycolytic subtype, blue. The enrichment score of glycolysis (D) and cholesterol biosynthesis (E) gene sets between the different mitophagy subtypes in TCGA LIHC cohort (F) Differences in HIF1A expression level among three mitophagy subtypes in TCGA LIHC cohort (G) Differences in mRNAi score among three mitophagy subtypes in TCGA LIHC cohort. The Kruskal-Wallis test was used to compare the statistical difference between three subtypes. GSEA results enriched in cluster A (H) and cluster B (I). The asterisks represented the statistical p value (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
mitophagyscores values were classified into the high-risk group (TCGA:n = 171; ICGC:n = 115). In the TCGA cohort, the low-risk group showed a significant advantage in OS (Figure 5A; HR = 1.88, 95%CI = 1.31−2.70, p < 0.001) and PFS (Figure 5B; HR = 1.61, 95%CI = 1.21−2.19, p = 0.0011). The median OS (3.7 years) and the median PFS (1.2 years) in the high-risk group were shorter than those in the low-risk group (median OS: 5.8 years; median PFS: 2.5 years). A similar result was observed in the ICGC-LIRI-JP cohort, that the high-risk group had a worse prognosis as compared to the low-risk group (Figure 5C; HR = 4.35, 95%CI = 2.07−9.17, p < 0.001).

The ROC curve was plotted to estimate the predictive ability of mitophagyscore. The area under the ROC curve for OS at 1-year was 0.77 in the TCGA-LIHC cohort and 0.75 in the ICGC-LIRI-JP cohort (Figure 5D, E).

FIGURE 5 | Kaplan-Meier plots for overall survival (OS) (A) and progression-free survival (PFS) (B) of HCC patients with a high or low mitophagyscore in TCGA-LIHC cohort (C) Kaplan-Meier plots for overall survival (OS) of HCC patients with a high or low mitophagyscore in ICGC cohort. ROC curves for predicting 1-year OS by mitophagyscore TCGA-LIHC cohort (D) and ICGC cohort (E).
FIGURE 6 | (A) The heatmap of gene expression in the high-risk group versus low-risk group for the mitophagy regulators in TCGA LIHC cohort. Violin plot of different mitophagy scores between different mitophagy subtypes (B), stages (C) and survival status (D) of TCGA LIHC cohort. (E) The heatmap of gene expression in the high-risk group versus low-risk group for the mitophagy regulators in ICGC cohort. Violin plot of different mitophagy scores between different mitophagy subtypes (F), stages (G) and survival status (H) of ICGC cohort. The asterisks represented the statistical p value (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
higher as compared to the advanced tumor stage (Figure 6C). Mitophagyscores of patients who died during the follow-up were significantly higher as compared to those who were alive (Figure 6D). In addition, identical findings were obtained in the ICGC-LIRI-JP cohort (Figure 6E–H).

Furthermore, we stratified both the TCGA-LIHC and ICGC-LIRI-JP cohorts based on clinical features and performed K-M survival analysis to determine whether the prognostic value of the mitophagyscores was independent of other clinical characteristics. The result indicated that mitophagyscores had satisfactory prognostic prediction efficacy in different groups stratified by clinical features (Supplementary Figure S2).

The prognostic nomogram was then constructed based on the stage and mitophagyscores to facilitate further clinical prognostic prediction (Figure 7A). The calibration curve for prediction of survival at 1-year (Figure 7B), 3-years (Figure 7C), and 5-years (Figure 7D) in the TCGA-LIHC cohort validated the predictive accuracy of the nomogram.

**Therapeutic Potential of Mitophagyscore in HCC**

Using the “Limma” package in R, a total of 197 upregulated genes and 64 downregulated genes were identified in the high-risk
group (Supplementary Figure S3A, B). The significant enrichment of biology processes was assessed using the “clusterProfiler” package in R; 20 GO terms and KEGG pathways with the smallest p-values are shown (Supplementary Figure S3E–F). In addition, each top 20 enriched KEGG and GO terms were validated on Metascape database and the results of the two methods were consistent. The details of functional enrichment analysis are provided in Supplementary Table S3.

CMap analysis was utilized to explore small molecular compounds having the potential to reverse the clinical manifestations in the high-risk group, such as the poor prognosis. A total of nine drugs met our selection criteria. The details of functional enrichment analysis are provided in Supplementary Table S3.

Candidate DEGs Highly Correlate With the Mitophagy Subtypes

Differential expression of SPP1 was identified as an important factor for diversity in mitophagy subtypes (Supplementary Figure S4). GEPIA-generated box plot was used to compare the tissue-based expression patterns of SPP1 between HCC (TCGA tumor) and paired normal adjacent tissue samples (TCGA normal + GTEx normal). The expression level of SPP1 was significantly high in tumors (p < 0.05) (Supplementary Figure S5A). The relative expression level of SPP1 was significantly lower in stage I tumor tissues (Supplementary Figure S5B). A high expression of SPP1 (>median value) indicated a worse prognosis of HCC patients (Supplementary Figure S5C). Additionally, IHC staining data from the HPA database indicated that SPP1 was significantly positively correlated with. (Supplementary Figure S5D). Three mitophagy alteration patterns were identified based on mitophagy regulators that may indicate the difference in mitophagy accumulation. Furthermore, the results demonstrated that high mitophagy accumulation was an indicator of poor prognosis. Comparatively, low mitophagy accumulation showed better prognoses in patients, particularly in the ICGC-LIRI-JP cohort.

Mitophagy, a specific autophagy type, guarantees the selective destruction of damaged or dysfunctional mitochondria. Because of the indispensable role of mitochondria in vital metabolic processes and bioenergetic functions, it is not unexpected that mitophagy is inextricably related to the metabolism of cancer cells to meet their bioenergetic needs. In pursuit of the mechanisms by which the high mitophagy subtype showed the worst prognoses, we turned our attention to the distinct metabolic patterns. Higher HIF1A expression level as compared to low mitophagy subtype indicated that in high mitophagy and intermediate subtype, tumors experienced greater hypoxic environments. Previous studies report that FUNDC1, a mitophagy regulator, interacts with LC3 through its typical LC3-binding motif Y (18)xxL (21), and mutation in this region impairs its interaction with LC3 and the subsequent induction of mitophagy under hypoxia; this may...

**TABLE 1** | small molecular compounds having the potential to reverse the clinical manifestations in the high-risk group.

| Cmap name   | Mean  | Enrichment | p     | Specificity |
|-------------|-------|------------|-------|-------------|
| DL-thiorphan| −0.788| −0.941     | 0.00742| 0.0171      |
| sanguinarine| −0.724| −0.884     | 0.02696| 0.08        |
| chrysin     | −0.749| −0.858     | 0.0571 | 0.0152      |
| blebbistatin| −0.7   | −0.855     | 0.04298| 0.0811      |
| metyrapone  | −0.727| −0.834     | 0.00137| 0.0053      |
| medrysone   | −0.757| −0.826     | 0.00006| 0.0054      |
| veropefolin | −0.731| −0.822     | 0.0113 | 0.0465      |
| apigenin    | −0.8   | −0.82      | 0.00199| 0.0272      |
| meticrane   | −0.756| −0.804     | 0.00064| 0.0         |

DISCUSSION

Mitophagy in inflammation, innate immunity, and tumor progression owing to the interplay between mitophagy regulators, has gained widespread attention from researchers. (Zhou et al., 2011), (Sliter et al., 2018) The majority of previous studies focus on individual regulators; the overall characterization of integrated roles of multiple mitophagy regulators has not yet been comprehensively elucidated. Recognizing the distinct mitophagy alteration patterns in HCC will deepen the insight for tumorigenesis and cancer progression and shed light for innovation on strategies for treatment and prognosis of HCC.

In our study, we investigated the mRNA expression levels of mitophagy regulators between normal and HCC samples, and found that the alterations of CNV could be the prominent factors resulting in perturbations on some mitophagy regulators expression, particularly on PINK1. Compared to normal tissues, PINK1 with the high-frequency of copy number losses showed significantly lower expression in HCC tissues. PINK1 was reported as the critical initiator of mitophagy (Lazarou et al., 2015). Therefore, such parallel relationships between CNV and gene expression in PINK1 may have contributed to the difference in the extent of mitophagy between HCC and normal tissues. In addition, three distinct mitophagy alteration patterns were identified based on mitophagy regulators that may indicate the difference in mitophagy accumulation. Furthermore, the results demonstrated that high mitophagy accumulation was an indicator of poor prognosis. Comparatively, low mitophagy accumulation showed better prognoses in patients, particularly in the ICGC-LIRI-JP cohort.

Mitophagy, a specific autophagy type, guarantees the selective destruction of damaged or dysfunctional mitochondria. Because of the indispensable role of mitochondria in vital metabolic processes and bioenergetic functions, it is not unexpected that mitophagy is inextricably related to the metabolism of cancer cells to meet their bioenergetic needs. In pursuit of the mechanisms by which the high mitophagy subtype showed the worst prognoses, we turned our attention to the distinct metabolic patterns. Higher HIF1A expression level as compared to low mitophagy subtype indicated that in high mitophagy and intermediate subtype, tumors experienced greater hypoxic environments. Previous studies report that FUNDC1, a mitophagy regulator, interacts with LC3 through its typical LC3-binding motif Y (18)xxL (21), and mutation in this region impairs its interaction with LC3 and the subsequent induction of mitophagy under hypoxia; this may...
be responsible for high mitophagy accumulation. Hypoxia leads to glycolysis and lactate production. Lactate, generated during glycolysis, decreases the tumor environmental pH and an acidic pH distinctly impedes the function of normal immune cells, such as T-cell and tumor-infiltrating lymphocytes. (Lardner, 2001), (Calcinotto et al., 2012) Furthermore, the lactate-mediated enhancement of tumor cell motility is reported not only in single-cell motion but also in enforced bulk migration (Goetze et al., 2011). Hyaluronan, synthesized by tumor-associated fibroblasts (TAF), increases around the carcinoma regions at high lactate concentrations and encourages the growth and motility of cancer cells. (Stern, 2008), (Walenta and Mueller-Klieser, 2004) Taken together, these findings may at least partially explain the facilitation of tumor progression and the worse prognosis in the high mitophagy subtype as compared to the low mitophagy subtype. Furthermore, by comparing the intermediate and high mitophagy subtypes, we found a particularly large difference in the mRNAsi score, a quantification for cancer stem cells (CSCs) characteristics. As tumor-initiating cells, the CSCs have the remarkable ability of self-renewal and give rise to cells of the same phenotype or tumor cell progenitors (Lapidot et al., 1994). CSCs are tightly linked with cancer drug resistance and poor prognosis. The lower mRNAsi score in the intermediate subtype may be one of the contributors to better prognosis of patients in this group. (Zhu et al., 2018), (Pei et al., 2020)

Cancer cells require high levels of cholesterol for membrane biogenesis and in general, cholesterol metabolism promotes cancer cell proliferation, migration and invasion (Huang et al.,

FIGURE 8 | A total of 21 potential therapeutic drugs in HCC with differential IC50 between high- and low-mitophagy score groups.
In our study, cholesterol biosynthesis pathway is the most enriched in low mitophagy subtype. This is hinting at the possibility of an interaction between cholesterol metabolism and mitophagy. Research by Vicente et al. indicates that intracellular cholesterol enrichment downregulate mitophagy induced by amyloid beta (Aβ). Moreover, cholesterol accumulation in mouse models of SREBF2 (a cholesterol-related transcription factor) over-expression reduces mitophagosome formation by causing cytosolic aggregation of the mitophagy adaptor OPTN (optineurin) (Roca-Agujetas et al., 2021). This is partly in agreement with our results.

Based on 12 mitophagy regulators, a risk score model (mitophagyscore) was constructed to estimate the accumulation of mitophagy; this was found to be a reliable prognostic indicator of HCC. The prognostic predictive ability of the mitophagyscore was stable across subgroups stratified by age, stage, T stage, and grade. To gain further insight into the clinical applicability and utility of mitophagyscore, the prognostic nomogram, a feasible tool to predict the probability of survival at 1-, 3-, and 5-years in patients with HCC was constructed. The cMap database and GDSC database allowed for an in-depth exploration of the association between the mitophagyscore and clinical treatment. Therapeutic small molecules that can reverse the mitophagy phenotype were obtained from the cMap database; these could provide new treatment opportunities for HCC. Thus, further experiments are needed to verify these findings. Additionally, we found that sensitivity towards 21 anti-tumor drugs was closely related to the mitophagyscore and this opened up promising perspectives for its potential clinical applicability, such as in the optimization of personalized therapy. Therefore, mitophagyscore not only functions as an independent prognostic tool to predict prognosis, but also triggers further thinking about the relationship between mitophagy and therapeutic agents for HCC. However, all the above results are based on bioinformatic mining of TCGA and ICGC databases, and more molecular biology-based experiments are required for their validation.

Due to the Spearman correlation analysis and the differential SPP1 expression across mitophagy subtypes, SPP1 may be an underlying reason for the mitophagy subtype specificity in HCC. Moreover, SPP1 may be a potential biomarker for the diagnosis and prognosis of HCC. SPP1 has previously been reported in the regulation of UPR- and ER stress-induced autophagy through intracellular S1P homeostasis (Lépine et al., 2011). However, the significance of SPP1 in association with mitophagy remains unclear. Our present study offered a fresh perspective on the mitophagic heterogeneity underlying HCC and identified a key gene, SPP1, which may contribute to the formation of three different mitophagy subtypes. The findings laid the groundwork for further exploration of mitophagy heterogeneity in HCC. However, further experimentation is required to verify these findings.

Our research provides new ideas and materials for the personalized clinical treatment plans for patients with HCC, although some limitations of this study should be acknowledged. Firstly, our study only included a bioinformatics analysis, lacking the validation of solid clinical specimens. Additionally, the research was conducted with a retrospective design rather than a prospective one. However, the present study was conducted in two independent cohorts, therefore, the result is still reliable and acceptable. Thus, future studies with prospective clinical trials and mechanistic exploration are warranted to further validate the present result.

**CONCLUSION**

In conclusion, using 26 mitophagy regulators, unsupervised clustering was performed to examine the mitophagy heterogeneity in HCC. The differential expression patterns of mitophagy regulators showed three distinct subtypes in HCC with extremely different mitophagy accumulation levels. Furthermore, different mitophagy subtypes showed distinct metabolic patterns and prognoses. The high mitophagy subtype had the poorest prognosis and highest glycolytic metabolism. Additionally, we constructed and validated a novel mitophagy-associated risk score system, which may provide a potential prognostic predictor for HCC. Moreover, based on the Cmap database, our results provided a range of small molecule compounds, which may ultimately pave the way for the implementation of targeted risk model-related treatments for HCC patients. We also demonstrated the difference in sensitivity towards potential anti-HCC drugs across the clusters and the findings were corroborated by previous research on mitophagy-associated risk phenotypes.

**DATA AVAILABILITY STATEMENT**

Publicly available datasets were analyzed in this study. This data can be found in The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/), Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) and International Cancer Genome Consortium (ICGC) data portal (https://icgc.org/).

**AUTHOR CONTRIBUTIONS**

YW, ZW and JS contributed equally to this work. YW and ZW: collection and analysis of data, and manuscript writing. YW and JS: analysis and interpretation of data. JS: data acquisition. YQ: project development and critical revision.

**FUNDING**

This research was funded by grants from the Key Research and Development (R&D) Program of Anhui Province (201904a07020047).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.799507/full#supplementary-material.
Wong, Y. C., and Holzbaur, E. L. F. (2014). Optineurin Is an Autophagy Receptor for Damaged Mitochondria in Parkin-Mediated Mitophagy that Is Disrupted by an ALS-Linked Mutation. *Proc. Natl. Acad. Sci. USA* 111, E4439–E4448. doi:10.1073/pnas.1405752111

Xu, M., Li, Y., Li, W., Zhao, Q., Zhang, Q., Le, K., et al. (2020). Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database. *Front. Med.* 7, 64. doi:10.3389/fmed.2020.00064

Zeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., et al. (2019). Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. *Cancer Immunol. Res.* 7 (5), 737–750. doi:10.1158/2326-6066.CIR-18-0436

Zhou, R., Yazdi, A. S., Menu, P., and Tschopp, J. (2011). A Role for Mitochondria in NLRP3 Inflammasome Activation. *Nature* 469, 221–225. doi:10.1038/nature09663

Zhu, C., Pan, Y., Ma, S., Cao, K., Zhou, S., Zhao, A., et al. (2018). Therapeutic Approaches Targeting Cancer Stem Cells. *J. Can. Res. Ther.* 14 (7), 1469–1475. doi:10.4103/jcrt.JCRT_976_17

Zoni, E., Minoli, M., Bovet, C., Wehrhan, A., Piscuoglio, S., Ng, C. K. Y., et al. (2019). Preoperative Plasma Fatty Acid Metabolites Inform Risk of Prostate Cancer Progression and May Be Used for Personalized Patient Stratification. *BMC cancer* 19, 1. doi:10.1186/s12885-019-6418-2

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2021 Wang, Wang, Sun and Qian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*